Osseon Therapeutics has named Gary Coughlen, certified public accountant (CPA), as chief financial officer (CFO). Coughlen was most recently CFO of PolyRemedy, a private-equity medical device company focused on wound care management.
Prior to PolyRemedy, he served as the CFO of Refractec, a manufacturer, and distributor of ophthalmic surgical devices to the global market. Coughlen started in 1999 at the founder’s stage with three employees and served as Refractec’s CFO through its growth to 75 employees.
Earlier in his career, Coughlen served as CFO at Scieran Technologies and was a vice president at Sierra Capital. He began his career in the public accounting at PricewaterhouseCoopers (PwC).
Coughlen is a graduate of University of Washington, where he earned a bachelor’s degree in Business Administration and UC-Berkley where he completed his MBA.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more